The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study
Abstract
Preclinical studies suggest ropinirole (a D2/D3 dopamine agonist) may be neuroprotective in Parkinson's disease (PD), and a pilot clinical study using 18 F‐dopa positron emission tomography (PET) suggested a slower loss of striatal dopamine storage with ropinirole compared with levodopa. This prospective, 2‐year, randomized, double‐blind, multinational study compared the rates of loss of dopamine‐terminal function in de novo patients with clinical and 18 F‐dopa PET evidence of early PD, randomized 1 to 1 to receive either ropinirole or levodopa. The primary outcome measure was reduction in putamen 18 F‐dopa uptake (Ki) between baseline and 2‐year PET. Of 186, 162 randomized patients were eligible for analysis. A blinded, central, region‐of‐interest analysis showed a significantly lower reduction (p = 0.022) in putamen Ki over 2 years with ropinirole (−13.4%; n = 68) compared with levodopa (−20.3%; n = 59; 95% confidence interval [CI], 0.65–13.06). Statistical parametric mapping localized lesser reductions in 18 F‐dopa uptake in the putamen and substantia nigra with ropinirole. The greatest Ki decrease in each group was in the putamen (ropinirole, −14.1%; levodopa, −22.9%; 95% CI, 4.24–13.3), but the decrease was significantly lower with ropinirole compared with levodopa (p < 0.001). Ropinirole is associated with slower progression of PD than levodopa as assessed by 18 F‐dopa PET. Ann Neurol 2003
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical parametric maps in functional imaging: A general linear approach
Friston, K. J., Holmes, A. P., Worsley, K. J., Poline, J. ‐., Frith, C. D., & Frackowiak, R. S. J. (1994) · Human Brain Mapping · doi:10.1002/hbm.460020402 · Cited by 9,688
The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.
Gibb, W. R., & Lees, A. J. (1988) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.51.6.745 · Cited by 3,481
Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale
Fahn, S. (1987) · Medical Entomology and Zoology · Cited by 2,163
Uneven Pattern of Dopamine Loss in the Striatum of Patients with Idiopathic Parkinson's Disease
Kish, S. J., Shannak, K., & Hornykiewicz, O. (1988) · New England Journal of Medicine · doi:10.1056/nejm198804073181402 · Cited by 1,953
Patlak, C. S., & Blasberg, R. G. (1985) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1985.87 · Cited by 1,673
Rascol, O., Brooks, D. J., Korczyn, A. D., De Deyn, P. P., Clarke, C. E., & Lang, A. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005183422004 · Cited by 1,539
Self-citationHalliwell, B. (2001) · Drugs & Aging · doi:10.2165/00002512-200118090-00004 · Cited by 1,502
Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's Disease
(1993) · New England Journal of Medicine · doi:10.1056/nejm199301213280305 · Cited by 1,221
Effect of Deprenyl on the Progression of Disability in Early Parkinson's Disease
The Parkinson Study Group* (1989) · New England Journal of Medicine · doi:10.1056/nejm198911163212004 · Cited by 917
Pramipexole vs Levodopa as initial treatment for Parkinson disease: A randomized controlled trial
Holloway, R. G., Shoulson, I., Kieburtz, K. D., McDermott, M., Tariot, P. N., Kamp, C., Day, D., Shinaman, A., Fahn, S., Lang, A. E., et al. (2000) · JAMA · Cited by 798
Self-citationPramipexole vs Levodopa as Initial Treatment for Parkinson Disease: A Randomized Controlled Trial
Parkinson Study Group (2000) · JAMA · doi:10.1001/jama.284.15.1931 · Cited by 767
Parkinson Study Group (2002) · JAMA · doi:10.1001/jama.287.13.1653 · Cited by 711
Understanding cell death in parkinson's disease
Jenner, P., & Olanow, C. W. (1998) · Annals of Neurology · doi:10.1002/ana.410440712 · Cited by 685
Irreversible motor impairment in young addicts ? ephedrone, manganism or both?
Sikk, K., Taba, P., Haldre, S., Bergquist, J., Nyholm, D., Zjablov, G., Asser, T., & Aquilonius, S.-M. (2007) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2007.00818.x · Cited by 665
Dopamine visualized in the basal ganglia of living man
Garnett, E. S., Firnau, G., & Nahmias, C. (1983) · Nature · doi:10.1038/305137a0 · Cited by 644
Self-citationBrooks, D. J., Ibanez, V., Sawle, G. V., Quinn, N., Lees, A. J., Mathias, C. J., Bannister, R., Marsden, C. D., & Frackowiak, R. S. J. (1990) · Annals of Neurology · doi:10.1002/ana.410280412 · Cited by 626
Self-citationMorrish, P. K., Rakshi, J. S., Bailey, D. L., Sawle, G. V., & Brooks, D. J. (1998) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.64.3.314 · Cited by 510
Self-citationStriatal dopaminergic function in restless legs syndrome: 18F-dopa and11C-raclopride PET studies
Turjanski, N., Lees, A. J., & Brooks, D. J. (1999) · Neurology · doi:10.1212/wnl.52.5.932 · Cited by 416
Self-citationAn [18F]dopa–PET and clinical study of the rate of progression in Parkinson’s disease
Morrish, P. K., Sawle, G. V., & Brooks, D. J. (1996) · Brain · doi:10.1093/brain/119.2.585 · Cited by 366
Self-citationSnow, B. J., Tooyama, I., McGeer, E. G., Yamada, T., Calne, D. B., Takahashi, H., & Kimura, H. (1993) · Annals of Neurology · doi:10.1002/ana.410340304 · Cited by 336
Nigrostriatal function in humans studied with positron emission tomography
Martin, W. R. W., Palmer, M. R., Patlak, C. S., & Calne, D. B. (1989) · Annals of Neurology · doi:10.1002/ana.410260407 · Cited by 282
Rakshi, J. S., Uema, T., Ito, K., Bailey, D. L., Morrish, P. K., Ashburner, J., Dagher, A., Jenkins, I. H., Friston, K. J., & Brooks, D. J. (1999) · Brain · doi:10.1093/brain/122.9.1637 · Cited by 270
Self-citationIida, M., Miyazaki, I., Tanaka, K.-I., Kabuto, H., Iwata-Ichikawa, E., & Ogawa, N. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01688-1 · Cited by 211
Correlation of striatal fluorodopa uptake in the MPTP Monkey with dopaminergic indices
Pate, B. D., Kawamata, T., Yamada, T., McGeer, E. G., Hewitt, K. A., Snow, B. J., Ruth, T. J., & Calne, D. B. (1993) · Annals of Neurology · doi:10.1002/ana.410340306 · Cited by 168
Oxidative Stress, Mitochondrial Respiration, and Parkinson's Disease
Cohen, G. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06180.x · Cited by 116
18 F‐dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease
Ceravolo, R., Piccini, P. P., Bailey, D. L., Jorga, K. M., Bryson, H., & Brooks, D. J. (2001) · Synapse · doi:10.1002/syn.10034 · Cited by 107
Self-citationIs There a Rationale for Neuroprotection Against Dopamine Toxicity in Parkinson's Disease?
Barzilai, A., Melamed, E., & Shirvan, A. (2001) · Cellular and Molecular Neurobiology · doi:10.1023/a:1010991020245 · Cited by 76
Rakshi, J. S., Pavese, N., Uema, T., Ito, K., Morrish, P., Bailey, D. L., & Brooks, D. J. (2002) · Journal of Neural Transmission · doi:10.1007/s00702-002-0753-0 · Cited by 59
Self-citationPeripheral markers of oxidative stress in Parkinson’s disease. the role of L-DOPA
Martignoni, E., Blandini, F., Godi, L., Desideri, S., Pacchetti, C., Mancini, F., & Nappi, G. (1999) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(99)00075-1 · Cited by 49
Cited by
Kalia, L. V., & Lang, A. E. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61393-3 · Cited by 6,184
Self-citationThe Parkinson Progression Marker Initiative (PPMI)
Marek, K., Jennings, D., Lasch, S., Siderowf, A., Tanner, C., Simuni, T., Coffey, C., Kieburtz, K., Flagg, E., Chowdhury, S., et al. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.09.005 · Cited by 1,892
Self-citationThe Role of Oxidative Stress in Parkinson's Disease
Dias, V., Junn, E., & Mouradian, M. M. (2013) · Journal of Parkinson’s Disease · doi:10.3233/jpd-130230 · Cited by 1,845
Levodopa and the Progression of Parkinson's Disease
(2004) · New England Journal of Medicine · doi:10.1056/nejmoa033447 · Cited by 1,821
Samii, A., Nutt, J. G., & Ransom, B. R. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16305-8 · Cited by 1,265
Metadata
- Authors
- Whone, A. L., Watts, R. L., Stoessl, A. J., Davis, M., Reske, S., Nahmias, C., Lang, A. E., Rascol, O., Ribeiro, M. J., Remy, P., Poewe, W. H., Hauser, R. A., Brooks, D. J., & REAL‐PET Study Group
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2003-06-25
- Volume
- 54
- Issue
- 1
- Pages
- 93-101
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W1997887984
- Cited by
- 829
- References
- 29
- FWCI
- 43.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.